Phelan–McDermid syndrome (PMDS) is a complex neurodevelopmental disorder characterized by global developmental delay, severely impaired speech, intellectual disability, and an increased risk of autism spectrum disorders (ASDs)1. PMDS is caused by heterozygous deletions of chromosome 22q13.3. Among the genes in the deleted region is SHANK3, which encodes a protein in the postsynaptic density (PSD)2,3. Rare mutations in SHANK3 have been associated with idiopathic ASDs4,5,6,7, non-syndromic intellectual disability8, and schizophrenia9. Although SHANK3 is considered to be the most likely candidate gene for the neurological abnormalities in PMDS patients10, the cellular and molecular phenotypes associated with this syndrome in human neurons are unknown. We generated induced pluripotent stem (iPS) cells from individuals with PMDS and autism and used them to produce functional neurons. We show that PMDS neurons have reduced SHANK3 expression and major defects in excitatory, but not inhibitory, synaptic transmission. Excitatory synaptic transmission in PMDS neurons can be corrected by restoring SHANK3 expression or by treating neurons with insulin-like growth factor 1 (IGF1). IGF1 treatment promotes formation of mature excitatory synapses that lack SHANK3 but contain PSD95 and N-methyl-d-aspartate (NMDA) receptors with fast deactivation kinetics. Our findings provide direct evidence for a disruption in the ratio of cellular excitation and inhibition in PMDS neurons, and point to a molecular pathway that can be recruited to restore it.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
We are grateful to participants and their families for their support; M. Adam for assistance with recruitment; to X. Jia, A. Cherry, C. Bangs, P. Jones, and J. Williams for assistance with tissue culture; P. Liao for help with multiplex ligation-dependent probe amplification (MLPA); M. Fabian for astrocyte preparations; H.N. Nguyen for consultations on the neural differentiation protocol and spectral karyotyping (SKY); V. Vu and G. Lin for help with data analysis; T. Sudhof, T. Boeckers, A. Grabruker, C. Garner and C. Sala for antibodies; R. Xavier for SHANK3 complementary DNA; R. Reijo-Pera and members of the Dolmetsch laboratory for commenting on the manuscript; E. Nigh for editing the manuscript. We also thank the Stanford Neuroscience Microscopy Service (supported by National Institutes of Health (NIH) NS069375). Support for this study came from the California Institute for Regenerative Medicine CIRM, the Autism Science Foundation and the Phelan-McDermid Syndrome Foundation (to A.S.), the Swiss National Science Foundation (to T.P.), the Japan Society for the Promotion of Research Abroad and American Heart Association (to M.Y.), the National Institute of Mental Health (NIMH) grant R33MH087898 (to J.F.H.); NIH Pioneer Award (5DP1OD3889), CIRM (grant RT2-01906) and Simons Foundation (to R.E.D.). We are also grateful for funding from the JDH research fund, N. Juaw, B. and F. Horowitz, M. McCafferey, B. and J. Packard, P. Kwan and K. Wang, and the Flora foundation.
This file contains Supplementary Figures 1-16 Supplementary Tables 1-5 and additional references.
About this article
Stem Cell Research & Therapy (2018)